The following analysts have issued research coverage on Protox Therapeutics. The opinions, estimates or forecasts regarding Protox's performance made by analysts are theirs alone and do not necessarily represent the opinions, forecasts or predictions of Protox or its management. Protox does not by its reference below or distribution imply its endorsement of or concurrence with such opinions, estimates or forecasts.

Versant Partners
Douglas W. Loe, Ph.D., MBA
dloe@versantpartners.com
416-849-5005

Loewen, Ondaatje, McCutcheon Limited
Connie S. Chen, PhD
cchen@lomltd.com
416-964-4448

What's New

June 2 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

April 29, 2010
Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

Stock Quote

	LAST TRADE:	$0.39
	TRADE TIME:	3:53PM EST
	CHANGE:	$0.00 (0.00%)
	PREV CLOSE:	$0.39
	OPEN:	$0.39
	BID:	$0.385
	ASK:	$0.39